<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400422</url>
  </required_header>
  <id_info>
    <org_study_id>Lipano 1 - Case</org_study_id>
    <nct_id>NCT04400422</nct_id>
  </id_info>
  <brief_title>Experience of Using Lipano in Children With Fatty Acid Oxidation Disorders</brief_title>
  <official_title>Experience of Using Lipano in Children With LCHAD (Long Chain Fatty Acid Oxidation Disorder)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Schär AG / SPA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Schär AG / SPA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a market research, observational study to evaluate the tolerability and acceptability
      of an MCT based formula for infants and young people with long chain fatty acid oxidation
      disorder from birth to 18 months. Patients with a confirmed diagnosis of a fatty acid
      oxidation disorder, which requires a specialist diet including MCT will be included in this
      study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal tolerance: questionnaire</measure>
    <time_frame>90 days</time_frame>
    <description>Daily questionnaire detailing any GI symptoms, severity and change from usual The collection of daily data about the gastrointestinal tolerance of the product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product compliance</measure>
    <time_frame>90 days</time_frame>
    <description>Daily questionnaire on amounts offered and amounts actually consumed, compared to recommended amount.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product palatability</measure>
    <time_frame>90 days</time_frame>
    <description>Questionnaire data captured to evaluate taste</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product acceptability</measure>
    <time_frame>90 days</time_frame>
    <description>Brief tick-box questionnaire on overall liking and acceptability of product</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemistry stability - creatine kinase</measure>
    <time_frame>90 days</time_frame>
    <description>creatine kinase will be monitored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry stability - liver enzymes</measure>
    <time_frame>90 days</time_frame>
    <description>liver enzymes will be monitored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry 1</measure>
    <time_frame>90 days</time_frame>
    <description>weight in g monitored to check growth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry 2</measure>
    <time_frame>90 days</time_frame>
    <description>height in cm monitored to check growth</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Fatty Acid Oxidation Disorder</condition>
  <arm_group>
    <arm_group_label>Lipano MCT formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kanso Lipano will be consumed daily for 3 months each to assess tolerability and compliance</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lipano formula</intervention_name>
    <description>Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD</description>
    <arm_group_label>Lipano MCT formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a fatty acid oxidation disorder requiring a ketogenic or a specialist
             diet as part of their treatment, which includes MCT.

          -  Patients from birth to 18 months

          -  Written informed consent obtained from patient or parental caregiver

        Exclusion Criteria:

          -  Presence of serious concurrent illness

          -  Investigator's uncertainty about the willingness or ability of the patient to comply
             with the protocol requirements

          -  Participation in any other studies involving investigational or marketed products
             concomitantly or within two weeks prior to entry into the study.

          -  Any patients having taken antibiotics over the previous 2 weeks leading up to the
             study

          -  Patients over 18 months of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Russian Children's Hospital Center for Orphan Diseases</name>
      <address>
        <city>Moscow</city>
        <zip>117513</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This study will be used to demonstrate acceptability for registration and reimbursement of these foods for special medical purposes.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

